Published in TB and Outbreaks Week, May 11th, 2004
Researchers at St. Louis University's Center for Vaccine Development and its clinical research organization, SoLUtions, are preparing to conduct a phase II human study of a new investigational anthrax vaccine developed by VaxGen, Inc.
"The goal is to develop an anthrax vaccine with better protection, an improved safety profile and a simpler dosing schedule," said Geoffrey J. Gorse, MD, principal investigator for the study and professor of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week